The efficacy and safety of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer
BackgroundWe aimed to report our clinical experience with the use of 225Ac-PSMA-617 in the treatment of mCRPC patients.MethodsA retrospective analysis was conducted on 29 metastatic castration-resistant prostate cancer (mCRPC) patients treated with 225Ac-PSMA-617. Patients underwent treatment at 8-w...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2025-02-01
|
| Seri Bilgileri: | Frontiers in Oncology |
| Konular: | |
| Online Erişim: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1516860/full |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|